Bryan Garnier - Media Analytics Corp (MEDA) MEDARTIS: Self-injured despite bang-in line FY18 numbers. Upgrade to Buy | BUY vs. NEUTRAL | CHF74.5 vs. CHF71

Report

Bryan Garnier

Hugo Solvet

MEDARTIS: Self-injured despite bang-in line FY18 numbers. Upgrade to Buy | BUY vs. NEUTRAL | CHF74.5 vs. CHF71

MEDARTIS - BUY vs. NEUTRAL | CHF74.5 vs. CHF71 (+28%)
Self-injured despite bang-in line FY18 numbers. Upgrade to Buy

Stepping-up organic growth
Misleading wording when it comes to an in-line margin
Share price back to very attractive levels, Upgrade to Buy
Updating peers multiple group and FV to EUR74.5

21/02/2019 3 EN

Underlying

Media Analytics Corp

See profile

US5843932014 Pink OTC Markets United States

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Hugo Solvet

Other Reports on these Companies

Independent Investment Research

Monthly LMI Update Independent Investment Research

Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked. This compares to the total dividends of 5 cents per share in FY20. The Board has confirmed that, in...

August 6, 2021 August 6, 2021 10 EN

Bryan Garnier

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS - BUY | CHF80(-11%) Remove Medartis from top picks after strong performance Medartis doubled YTD, and returned 28% since entering top picks Extremities still offers great growth to LT investors Largest opportunities still ahead Retain BUY TP CHF80, inorganic growth key catalyst for share

June 10, 2021 June 10, 2021 4 EN

Bryan Garnier

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

MEDARTIS - BUY | CHF80 VS. 60(-2%) Reaching for the stars, in post-COVID extremities US strategy paying off KeriMedical allows Medartis to touch new markets More M&A on the agenda Update estimates TP EUR 80 (from EUR 60), retain BUY

March 30, 2021 March 30, 2021 3 EN

Ebusco: The expert e-bus platform

Following the publication of our industry note entitled "Electrifying the future of on-road HDVs", we initiate coverage of Ebusco with a Buy rating and a price target of EUR5.5.Founded in 2012, Ebusco is a Dutch designer and manufacturer of fully electric transit-buses, both for city or regional us

May 16, 2024 May 16, 2024 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Nikola Corp: The dual e-trucking arm

Following the publication of our industry note entitled "Electrifying the future of on-road HDVs", we initiate coverage of Nikola Corp with a Buy rating and a price target of USD1.0.Founded in 2015, Nikola is a pioneering American designer and manufacturer of ZE HDV class 8 trucks, leveraging both

May 16, 2024 May 16, 2024 1 EN

Paul de Froment ... (+3)

Paul de Froment
Sebastián Marroquin Mérida
Thomas Mordelle

Electrifying the future of on-road HDVs

Road transport accounts for about 75% of transport emissions worldwide and is responsible for around 21% of total emissions. More than a third is directly related to medium and heavy-duty vehicles (MHDV) i.e. buses and trucks, the bulk of which relates to freight.With major economies gradually alig

May 16, 2024 May 16, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

MEDARTIS: Self-injured despite bang-in line FY18 numbers. Upgrade to Buy | BUY vs. NEUTRAL | CHF74.5 vs. CHF71

Monthly LMI Update Independent Investment Research

MEDARTIS: Remove Medartis from top picks after strong performance | BUY | CHF80(-11%)

MEDARTIS: Reaching for the stars, in post-COVID extremities | BUY | CHF80 VS. 60(-2%)

Ebusco: The expert e-bus platform

Nikola Corp: The dual e-trucking arm

Electrifying the future of on-road HDVs

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe